Zenotech Lab Peer Comparison

BSE: 532039

₹38.08

₹-0.26 (-0.68%)

As on 03-Nov-2026IST

Market cap

₹232 Cr

Revenue (TTM)

₹41 Cr

P/E Ratio

--

P/B Ratio

2.5

Div. Yield

0 %

Edit

	Zenotech Lab	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Market cap (₹ Cr)	232	18,204	17,954	17,370	16,335
Revenue (₹ Cr)	41	1,682	2,287	2,570	3,330
Net Profit (₹ Cr)	-4.25	273.51	678.07	735.15	720.77
Net Margin (%)	-10.03	16.19	28.10	26.88	21.60
RoE (%)	-4.50	11.15	19.73	19.16	18.93
Price to Earnings	--	61.23	26.98	23.63	23.09
Price-To-Book	2.52	6.78	4.89	3.94	3.94

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Zenotech Lab	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Operating Revenue	43.61	1,538.87	2,187.19	2,519.65	3,129.42
Total Income	45.92	1,602.52	2,302.73	2,707.60	3,147.87
Total Expenditure	34.43	1,157.98	1,426.34	1,615.47	2,020.01
EBITDA	9.19	380.89	760.85	904.18	1,109.41
Depreciation	7.11	119.72	72.77	57.73	279.50
EBIT	2.08	261.17	688.08	846.45	829.91
Interest	--	58.79	0.87	9.57	192.67
Other Income	2.31	63.65	115.54	187.95	18.45
Exceptional Items	-0.20	12.16	--	-49.16	-17.24
Profit before Tax	4.19	295.31	802.79	975.67	638.54
Provision for Tax	5.26	51.98	153.06	253.24	-8.97
Profit after Tax	-1.07	243.33	649.73	722.43	647.51

Liabilities (₹ Cr)

	Zenotech Lab	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Shareholder's Funds	95.12	2,591.20	3,586.42	4,202.90	3,902.67
Minority Interest	--	1.04	44.38	--	-7.01
Non-Current Liabilities	3.98	249.46	20.75	19.19	1,149.84
Current Liabilities	12.06	848.06	385.96	627.48	2,201.22
Total Liabilities	111.15	3,705.61	4,037.51	4,921.88	7,246.72

Assets (₹ Cr)

	Zenotech Lab	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Non-Current Assets	70.11	2,578.95	1,451.85	1,046.35	5,582.75
Current Assets	41.04	1,109.77	2,585.66	3,803.22	1,663.97
Total Assets	111.15	3,705.61	4,037.51	4,921.88	7,246.72
Total Debt*	0.00	657.97	0.57	2.50	2,309.68
Net Current Assets	28.98	261.71	2,199.70	3,175.74	-537.25
Contingent Liabilities	1.05	160.01	17.53	370.49	51.57

Cashflow (₹ Cr)

	Zenotech Lab	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Cash From Operating Activities	10.20	342.18	523.24	967.57	537.99
Cash Flow from Investing Activities	-6.49	-325.92	-582.30	-561.67	-369.46
Cash from Financing Activities	--	13.62	-46.46	-798.31	-313.53
Net Cash Inflow / Outflow	3.71	29.88	-105.52	-392.41	-145.00

Ratios

Profitability Ratios

	Zenotech Lab	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
ROCE (%)	4.38	11.43	24.97	23.39	14.47
ROE (%)	-1.12	9.82	20.79	17.16	19.23
ROA (%)	-0.98	6.97	17.94	14.91	9.18
EBIT Margin (%)	26.36	28.89	40.07	43.34	36.04
Net Margin (%)	-2.33	15.18	28.22	26.68	20.57
Cash Profit Margin (%)	13.85	23.59	33.03	29.72	28.49

Growth Ratios

	Zenotech Lab	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Revenue Growth (%)	1.32	19.62	12.89	10.45	8.15
EBIT Growth (%)	-26.90	29.72	17.90	19.68	8.91
Net Profit Growth (%)	-119.10	210.81	20.08	-5.88	72.82
EPS Growth (%)	-119.10	210.80	19.57	-5.88	73.16
Book Value Growth (%)	-1.05	9.67	26.75	-0.34	36.71

Valuation Ratios

	Zenotech Lab	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Price / Earnings	0.00	28.03	17.84	29.89	29.02
Price / Book Value	2.20	2.63	3.27	5.14	4.62
Dividend Yield (%)	0.00	0.17	0.53	1.59	0.00
EV/EBITDA	15.56	16.72	12.43	16.93	17.93
Market Cap (₹ Cr)	209.28	6,819.66	11,439.22	21,592.90	17,980.08

Solvency Ratios

	Zenotech Lab	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Debt to Equity	0.00	0.25	0.00	0.00	0.59
Short term debt to equity ratio	--	0.16	0.00	0.00	0.12
Current Ratio	3.40	1.31	6.70	6.06	0.76
Quick Ratio	3.40	0.88	5.59	5.31	0.56
Interest Coverage	--	6.02	923.75	102.95	4.31

Operating Efficiency Ratios

	Zenotech Lab	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Debtors to sales (%)	20.12	33.72	37.76	7.22	21.74
Asset Turnover	0.40	0.44	0.60	0.54	0.46
Receivable days	67.92	113.81	121.68	26.06	63.88
Inventory Days	0.00	84.76	63.83	65.95	43.27
Payable days	1,263.19	101.94	108.28	81.01	151.85
Cash Conversion Cycle	-1,217.81	96.62	77.23	11.00	-44.70

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.